Retail chatter around Crinetics Pharmaceuticals picked up late Sunday after the company released long-term data for its oral ...

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATH ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, ...

Tesamorelin, a synthetic growth hormone-releasing hormone (GHRH) analog, has garnered significant attention in scientific ...

Growth Hormone-Releasing Peptide-2 (GHRP-2) is a synthetic hexapeptide that has garnered significant attention in the ...

The type 1 insulin-like growth factor I (IGF-IR) receptor plays a significant role in the growth of normal and abnormal cells, and antibodies against the IGF-IR are now in clinical trials.

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

The original methods for targeting the IGF-I receptor in experimental animals were antisense strategies and dominant-negative mutants of the receptor. They are obsolete. Several antibodies to the ...

In a paper published in Diabetes, they show that, in Type 1 diabetes patients, verapamil prevented the decline of the hormone insulin-like growth factor 1, or IGF-1, as compared to controls who did ...